With Two BCMA-Targeting Myeloma Treatments, Which Should Be First Choice?

Experts Weigh In On Positioning BMS/Bluebird’s Abecma And GSK’s Blenrep

Market Snapshot: GSK's Blenrep and BMS's Abecma are the first of many drugs for the late-line setting. In many cases, the CAR-T may be the first choice, but some patients are unable to handle it or risk progressing while awaiting treatment.

Open Book Of prostate multiple myeloma, Conceptual Image - Image — With two BCMA-targeting myeloma therapies available, the question now is how to position them in treatment • Source: Shutterstock

With two BCMA-targeting therapies now approved for multiple myeloma – GlaxoSmithKline plc’s antibody-drug conjugate Blenrep (belantamab mafodotin-blml) and bluebird bio/Bristol Myers Squibb Company’s CAR-T therapy Abecma (idecabtagene vicleucel) – the question becomes how their differences in efficacy, toxicity and logistics determine which will be the first option for patients. That will be especially pertinent as more anti-BCMA therapies become available in the coming years.

In the first quarter of 2021, Blenrep had sales of £21m ($29m), the London-based drug maker announced 28 April. In...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

IgAN Market Snapshot: Growing Market, But Patient Segmentation Still A Question

07 Jan 2025

• By Alaric DeArment

IgA nephropathy has gone from having zero to three approved treatments in just a few years, with over half a dozen more in late-stage development. But there are still many unknowns.

Atopic Dermatitis Market Snapshot: A Crowded Field With Room To Grow

11 Dec 2024

• By Jessica Merrill

Topical, oral and biologic drugs have made a difference for patients with atopic dermatitis, but full control remains elusive for many, with the heterogeneous condition, leaving open a door for new medications.

Myeloma Market Snapshot: New Drug Classes On The Way, But Cost Could Be A Problem

29 Jul 2023

• By Alaric DeArment

More BCMA-directed therapies are in development, as well as ones targeting GPRC5D and FcRH5, along with CELMoDs. The question is how to bring those into therapy and pay for them.

Myeloma Market Snapshot: Backlogs Dog BCMA CAR-Ts As Treatment Paradigm Evolves

26 Jul 2023

• By Alaric DeArment

KOLs told Scrip about how they are incorporating new immunotherapies into treatment and combining existing agents, but some new drug classes have struggled to take root.